The efficacy and safety of basiliximab, in combination with different maintenance regimens, are extensively addressed in the available literature. Basiliximab reduces the incidence of acute rejection, allows a safe reduction of steroid dosage, and is associated with economic savings, although there is substantially no proof that basiliximab prolongs either patient or graft survival. Initial basiliximab administration entails a low-risk and is associated with fewer adverse events than T cell depleting agents. However, life-threatening reactions were reported following re-exposure to basiliximab in recipients who lost graft function early after transplantation and, therefore, discontinued all immunosuppressive agents.
|Autori:||U. Boggi;F. Vistoli;S. Signori;M. Del Chiaro;G. Amorese;M. Barsotti;G. Rizzo;P. Marchetti;R. Danesi;M. Del Tacca;F. Mosca|
|Titolo:||Efficacy and safety of basiliximab in kidney transplantation.|
|Anno del prodotto:||2005|
|Digital Object Identifier (DOI):||10.1517/14740322.214.171.1243|
|Appare nelle tipologie:||1.1 Articolo in rivista|